Hinge Health Director Kristina Leslie Sells 1,200 Shares for $105,876
Key Points
The transaction reduced her direct equity position by 4% while maintaining a multi-million dollar stake in the company.
This disposition involved directly held shares only, with no indirect holdings reported in the filing.
The sale was valued at just under $106,000.
- 10 stocks we like better than Hinge Health ›
Kristina M. Leslie, a Director at Hinge Health (NYSE:HNGE), disposed of 1,200 shares of Class A common stock on Aug. 20, 2026, according to a recent SEC Form 4 filing.
Transaction summary
| Metric | Value |
|---|---|
| Shares sold (directly held) | 1,200 |
| Transaction value | $105,876 |
| Post-transaction shares (directly held) | 30,387 |
| Post-transaction value | $2.6 million |
Transaction value based on SEC Form 4 weighted average sale price ($88.23); post-transaction value based on Aug. 20, 2026, market close ($85.62).
Key questions
- How does this sale impact the director's total equity exposure?
Leslie retains a direct interest of 30,387 shares in Hinge Health after the reduction in her Class A common stock holdings. - What is the current market valuation of the insider's remaining position?
As of the Aug. 20, 2026, market close, the director's remaining direct equity is valued at approximately $2.6 million. - What has been the stock's performance trajectory over the last year?
The company has seen a total return of 50% for the one-year period ending on the transaction date of Aug. 20, 2026. - What is the insider's overall ownership level following this transaction?
Based on the latest available data, the director holds a 0.03% ownership stake in the healthcare information services provider.
Company Overview
| Metric | Value |
|---|---|
| Share Price (as of market close 2026-08-20) | $85.62 |
| Market Capitalization | $7.4 billion |
| Revenue (TTM) | $720 million |
| Net Income (TTM) | $107.2 million |
Company Snapshot
- Hinge Health develops specialized healthcare software solutions focused on musculoskeletal and joint health, delivering comprehensive digital platforms that address general musculoskeletal care, acute injuries, chronic pain management, and post-operative rehabilitation across its customer base.
- The company operates a software-as-a-service business model that generates revenue through licensing its advanced digital health platform to employers, health plans, and healthcare providers seeking to optimize musculoskeletal care delivery and reduce associated costs.
- Hinge Health primarily serves large employers and health plans seeking to improve clinical outcomes and reduce healthcare expenditures related to musculoskeletal conditions, representing a significant and growing addressable market within the digital health sector.
Founded in 2012 and headquartered in San Francisco, Hinge Health has established itself as a specialized digital health provider with a market capitalization of $6.6 billion and TTM revenues of $720 million. The company's platform delivers integrated musculoskeletal care solutions that combine clinical expertise with advanced technology to address one of the most prevalent and costly categories of healthcare conditions. With 1,437 employees and demonstrated profitability, Hinge Health maintains a competitive position in the healthcare information services sector through its focused specialization and comprehensive approach to musculoskeletal health management.
What this transaction means for investors
This transaction doesn't appear to qualify as a cause for concern for shareholders. The first reason is that, as of this writing, the stock price has climbed 98.6% thus far in 2026. In comparison, the S&P 500 is up 12.8% over the same period. That is suggestive of Leslie just taking some profits off the table after such a strong run-up in the stock price. The second reason is that only 1,200 shares were sold while over 30,000 were retained. That shows continued alignment with the company's future success, so putting all that together, it indicates this is likely just a routine sale.
In the near term, analysts are typically bullish on where the Hinge Health stock price will go next. According to CNN, of the 16 analysts who cover the stock, 94% rate it a buy, while 6% rate it a hold. That group forecasts the stock could climb to $105 over the next 12 months, representing a 13.6% gain from today's price. The highest price target in the group is $140, implying a potential gain of 51.5%, while the lowest is $85, implying a potential loss of nearly 8%.
Should you buy stock in Hinge Health right now?
Before you buy stock in Hinge Health, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Hinge Health wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $445,833!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,402,153!*
Now, it’s worth noting Stock Advisor’s total average return is 993% — a market-crushing outperformance compared to 214% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of September 4, 2026.
Jack Delaney has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Hinge Health. The Motley Fool has a disclosure policy.
Recommended Articles
